Compare Regeneron Pharmaceuticals Inc (REGN) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Simon Property Group Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while Simon Property Group Inc trades at $199.6 (market cap $63.93B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Simon Property Group Inc pays the higher dividend (4.5%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Simon Property Group Inc for 99 Days on average.
| REGN | SPG | |
|---|---|---|
Market Cap | $76.40B | $63.93B |
Volume | 626,381 | 1,228,229 |
Sector | Health | Real Estate |
52-Week High | $852.03 | $236.70 |
52-Week Low | $557.73 | $173.35 |
Typical Hold Time | 107 Days | 99 Days |
Enterprise Value | $71.12B | $92.38B |
Dividend Yield | 0.51% | 4.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
SPG trades at $197.59, down 2.06% amid bearish technical signals, though fundamentals show strength with Q4 2025 EPS beating estimates at $9.35 versus $1.90 expected. The company maintains robust profitability with 66.57% net income margin and 135.7% ROE, while recent news highlights strong leasing demand and a new media network launch to monetize mall traffic.
Outlook is mixed: analyst consensus targets $222.90 (12.8% upside) with 42% buy ratings, but technical indicators signal caution. Key risks include $24.21B long-term debt and sensitivity to interest rates, though A-rated balance sheet and dividend yield near 4.5% offer support. Revenue growth to $6.9B in 2026 suggests stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
